A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects

11 Jul 2012

• By John Davis

Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.

German drug discovery company Evotec AG believes it may have hit upon a new model for industry-academia research collaborations in its year-old tie-up with the Harvard University laboratory of Prof. Douglas Melton.

Not only has their "CureBeta" initiative on regenerating insulin-producing beta-cells in type 1 and type 2 diabetes found a new...